Health Logic Interactive Receives Letter of Support from the Chief of the Division of Nephrology at Johns Hopkins University School of Medicine

CALGARY, AB, May 26, 2021 /CNW/ – Health Logic Interactive Inc. (“Health Logic” or the “Company“) (TSXV: CHIP.H)(OTCPK: CHYPF), is pleased to announce its wholly-owned operating subsidiary, My Health Logic Inc. (“My Health Logic“), has received a letter of support on the Company’s chronic kidney disease (CKD) technology from nephrologist Chirag R. Parikh, MD, PhD Director, Division of Nephrology at Johns Hopkins University School of Medicine. This letter supports the Company’s belief that its lab-on-chip device for the early detection of CKD has the potential to address a large and unmet need of patients who have, or are at risk for developing, CKD.

In his support letter, Dr. Parikh stated, “As the Chief of the Division of Nephrology and the Ronald Peterson Professor of Medicine at the Johns Hopkins University School of Medicine, I have the responsibility to manage our division’s clinical and research efforts as well as coordinate care delivery for the at-risk population in Baltimore and surrounding areas. Many patients at the highest risk for CKD do not have access to screening, and there is no convenient method for at home/easily accessible devices for patients who require routine monitoring of urine albumin for follow up of their glomerular disease.  Your proposed device and health delivery platform has an opportunity to transform this space by making screening feasible at every health encounter and potentially at home. ”

When asked about this support letter from Dr. Parikh, Dr. Tangri, a member of the Company’s scientific development team and one of the co-founders of the device, stated that “according to the CDC more than 100 million Americans are at risk for having CKD, and more than 30 million already have the disease and are at risk for kidney failure and heart attacks. I am delighted that Dr. Parikh shares our vision for improving screening and treatment for patients with or at risk of CKD, and is a believer in upstream interventions that can identify high risk patients for early treatment and disease prevention.”

Company Article Featured in Stat News

The Company is also excited to announce its feature in Stat News, a trusted journalistic website with a focus on health, medicine, and the life sciences.

About the Company

Health Logic Interactive, through its wholly owned operating subsidiary My Health Logic, is developing and commercializing consumer focused handheld point-of-care diagnostic devices that connect to patient’s smartphones and digital continued care platforms. The Company plans to use its patent pending lab-on-chip technology to provide rapid results and facilitate the transfer of that data from the diagnostic device to the patient’s smartphone. The Company expects this data collection will allow it to better assess patient risk profiles and provide better patient outcomes. Our mission is to empower people with the ability to get early detection anytime, anywhere with actionable digital management for chronic kidney disease. For more information visit us at: www.healthlogicinteractive.com

Further information regarding Health Logic Interactive Inc. and its disclosure documents are available on SEDAR at www.sedar.com.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Notes

Certain statements contained in this press release constitute “forward-looking statements”. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company’s belief that it will receive approval from the United States Food and Drug Administration for its device, that the device has the potential to address a large and unmet need of patients who have, or are at risk for developing, CKD, the potential of the device to make screening feasible at every health encounter and potentially at home, and the Company’s strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company’s Management’s Discussion and Analysis for the year ended December 31, 2020. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law.

SOURCE Health Logic Interactive Inc.

For further information: George Kovalyov, Director, info@healthlogicinteractive.com, 1-877-456-4424.

Health Logic Interactive Letter to Shareholders

Dear Shareholders of Health Logic,

This is our first letter to the shareholders of Health Logic Interactive Inc.  As your CEO, I intend to communicate to you at least quarterly with respect to the state of our business, our significant milestones and achievements, our challenges, our goals, and any new material additions to our organization.

I am extremely excited about our plans to integrate our innovative point-of-care (POC), lab-on-chip (LoC), digital diagnostic technology for Chronic Kidney Disease (CKD) with our digital platform strategy to provide risk analysis, disease education materials, and hold key patient data. Our goal and expectation is for all of this to be possible within the capabilities of your smartphone.

I am also pleased with the strategic build-out of our leadership team, which now includes Dr. Claudio Rigatto as our elected Chief Medical Officer (CMO) and Harrison Ross as our Chief Financial Officer (CFO). We will continue to add key members as the Company grows.

We are looking forward to the year ahead as we work to accelerate development of our assets with the aim to execute on our ultimate objective: to increase the value of your investment. We are keenly focused on bringing to market a collection of innovative healthcare technologies which we believe will have a positive disruptive effect on the rapidly growing CKD space. In particular, we are focused on development of: (a) the existing Lab-on-Chip MATLOC product platform; and (b) our LoC digital hand-held diagnostic device.

Over the next few months, we intend to achieve the following milestones:

  1. Plan and announce a capital financing.
  2. Continue to work with strategic partners for product development, regulatory and digital software strategy, and implementation.
  3. Begin work with our regulatory partner on the 510(k) Accelerated FDA Approval Process.
  4. Identify 510(k) pathway for approval through pre-submission FDA meeting.
  5. Build out Scientific Advisory Board.
  6. Hold initial virtual Scientific Advisory Board Meeting.
  7. Identify additional needed resources for quality management and document control with respect to the FDA submission, and develop digital strategy for product awareness and positioning.
  8. Continue the work commenced by Dr. Lin, co-founder of our LoC technology, to develop and validate our LoC Platform Technology for CKD assessment and diagnosis.
  9. Continue discussions with potential strategic investment partners.

We believe that achieving these strategic milestones in parallel over the next few months will allow us to advance our technology to achieve product release in 2022 and create increased value for our shareholders. Though we are still an early-stage development and commercialization company with many challenging milestones ahead, we are passionately committed to executing on our objectives and motivated by our potential as a company to not only increase shareholder value but effect positive change while doing so.

We are committed to cultivating a strong relationship with the shareholders of Health Logic and intend to do so by building and maintaining a culture of transparency, over-communication, accountability, and integrity. I look forward to providing you with updates on our progress and sharing the growth activities and initiatives that we are focused on and excited about from time to time. In the meantime, if you have any questions or concerns, please feel free to reach out to me by email at david@healthlogicinteractive.com or by telephone at 1-877-456-4424, or visit our website which is now live at www.healthlogicinteractive.com.

Thank you for your support as a Health Logic shareholder. I look forward to continuing our journey together.

All the best,

HEALTH LOGIC INTERACTIVE INC.

Per: David Barthel, CEO

About the Company

Health Logic Interactive Inc., through its wholly owned operating subsidiary My Health Logic, is developing and commercializing consumer focused handheld point-of-care diagnostic devices that connect to patient’s smartphones and digital continued care platforms. The Company plans to use their patent pending lab-on-chip technology to provide rapid results and facilitate the transfer of that data from the diagnostic device to the patient’s smartphone. The Company expects this data collection will allow it to better assess patient risk profiles and provide better patient outcomes. Our mission is to empower people with the ability to get early detection anytime, anywhere with actionable digital management for chronic kidney disease. For more information visit us at: www.myhealthlogic.com

Further information regarding Health Logic Interactive Inc. and its disclosure documents are available on SEDAR at www.sedar.com.

Forward Looking Statements

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements, referred to herein as “forward–looking statements”, are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management’s expectations and intentions with respect to, among other things: the frequency and substance of ongoing communications with shareholders; the integration of LoC diagnostic technology with the Company’s digital platform strategy, and the functionality and smartphone compatibility of such integration; the Company’s milestones and anticipated benefits of achieving the milestones within the next 3-9 months; and building and maintaining a culture of transparency, over-communication, accountability, and integrity.   

These forward–looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the Company’s ability to provide updates to its shareholders as stated; the Company’s ability to integrate LoC diagnostic technology with the Company’s digital platform strategy to provide risk analysis, disease education materials, and hold key patient data, and to make all of this smartphone compatible; the Company’s ability to achieve the milestones in the next 3-9 months or at all, and the anticipated benefits of any such achievement; and the Company’s ability to build and maintain a culture of transparency, over-communication, accountability, and integrity.

In making the forward looking statements in this news release, the Company has applied several material assumptions, including without limitation, that: the Company will be able to provide updates to its shareholders as stated; the Company will be able to integrate LoC diagnostic technology with the Company’s digital platform strategy to provide risk analysis, disease education materials, and hold key patient data, and to make all of this smartphone compatible; the Company will be able to achieve the milestones in the next 3-9 months, and such achievement will result in the benefits stated; and the Company will be able to build and maintain a culture of transparency, over-communication, accountability, and integrity.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

SOURCE Health Logic Interactive Inc.

For further information: George Kovalyov, COO, info@healthlogicinteractive.com, 1-877-456-4424.

Health Logic Interactive Inc., Acquires Next-Generation Lab-On-Chip Medical Diagnostic Technology

CALGARYMarch 29, 2021 /CNW/ – Health Logic Interactive Inc. (“Health Logic” or the “Company“) (TSXV: CHIP.H) (OTCPK: FNNGF), is pleased to announce its wholly owned operating subsidiary, My Health Logic Inc. (“My Health Logic“), has entered into a license agreement (the “License Agreement“) with an arm’s length third party (the “Licensor“) pursuant to which My Health Logic has a worldwide, exclusive license to the UAL-Chip, a patent pending lab-on-chip (“LOC“) technology that has the potential to be used in a smartphone connected, hand-held device to provide rapid point-of-care (“POC“) diagnosis of Chronic Kidney Disease (“CKD“).

CKD is a life-changing chronic condition that is harmful for patients and extremely expensive to treat unless caught early. Over 850 million people globally and 37 million people in the United States have CKD, and total healthcare costs for treatment of CKD in the US exceed $120B per year. The key to preventing the major harms from CKD, such as kidney failure, kidney dialysis, and death, is early testing and treatment; however, approximately 90% of those afflicted by CKD do not realize they have it. We believe that providing patients and caregivers a low-cost, accessible tool for early diagnosis and treatment is an opportunity to help millions of at-risk patients and start to bend the cost curve for health systems worldwide.

UAL-Chip technology has the potential to drive a much-needed disruption of the legacy systems used for CKD testing and accelerate the trend towards automation, digitization and personalization in the healthcare industry. The UAL-Chip can utilize microfluidic technology to test for the albumin levels in urine and deliver rapid results to a users’ smartphone and their healthcare practitioner. Currently, <50% of at-risk patients are tested; we expect that introducing digitally connected home testing solutions would increase this number by removing one of the current barriers to testing, being attendance at a central lab, and would also provide My Health Logic with the opportunity to develop a robust platform for continuous digital patient monitoring and care for CKD of all stages.

“CKD is common, costly and harmful for patients and communities. It is also under-recognized. Bringing the CKD diagnosis into the home is a disruptive approach that could bridge the screening gap for millions of patients, allowing early detection and treatment, preventing harms for millions, and reducing health costs by billions” – Dr. Claudio Rigatto, Co-Inventor, Seven Oaks General Hospital

“Our lab-on-chip platform can give accurate results rivalling central laboratories in precision but in an accessible, low cost and rapid form usable in the home, fulfilling the dream of true point-of-care diagnosis and personalized medicine.” – Dr. Francis Lin, Lead Inventor

Highlights of the Market:

  • CKD is the 8th leading cause of death in the US.
  • Estimated that 15% of all people in the US are at risk of CKD yet 90% are unaware they have the disease.
  • Medicare spent $120 billion on all CKD related costs in 2017.
  • End Stage Renal Disease (ESRD) caused by CKD led to $36 billion in Medicare-related costs in 2017.
  • o ESRD includes kidney failure, dialysis, and transplant.
  • American Kidney Health Initiatives passed in 2019.
  • The global POC market has been growing at a CAGR of 10.2% and the global digital remote health market is expected to grow at a CAGR of 27.9% through to 2026.
  • Sources: www.kidney.orgwww.uofmhealth.comwww.grandviewresearch.comwww.businesswire.com

Highlights of the Technology:

  • Proof of concept trial complete in clinical setting showing successful results.
  • Patent pending technology with USTPO Patent number.
  • The UAL-Chip is being built so that results will connect to a users’ phone and provide feedback in less than 5 minutes. The plan is to collect the data through My Health Logic’s MATLOC device, a hand-held POC device currently in development, and store the data on the My Health Logic continued care platform.
  • 510 (k) pre-market FDA submission plans – accelerated regulatory pathway.
  • Planned development of urine ACR and blood eGFR (the two necessary tests needed for accurate CKD assessment).
  • First-movers advantage – there are currently no available hand-held, POC diagnostics on the market that quantitatively measure both ACR and eGFR.
  • Co-founders and inventors of the technology plan to join My Health Logic in key leadership positions and continue to advance development, including:
    • Dr. Francis Lin
    • Dr. Claudio Rigatto
    • Dr. Paul Komenda
    • Dr. Navdeep Tangri

The Technology was invented by the world-renowned team of nephrologists at Seven Oaks General Hospital including Dr. Navdeep Tangri, Dr. Paul Komenda, and Dr. Claudio Rigatto, and biomedical engineering LOC expert Dr. Francis Lin. The team of inventors are expected to play an active role in the ongoing development of the lab-on-chips, and MATLOC device as we pursue regulatory approvals with Health Canada and the US Food and Drug Administration (“FDA“) via an accelerated 510K pathway. In addition to the ongoing guidance from the inventors, the Company plans to on board and engage strategic industry thought leaders and experts to best guide My Health Logic through the development process to successful commercialization, for which there is no guarantee.

My Health Logic’s obligations under the License Agreement include: (a) developing, manufacturing and selling products that incorporate the licensed technology (“Licensed Products“); (b) marketing Licensed Products in the US and Canada within 6 months of receiving regulatory approval; (c) reasonably filling market demand for Licensed Products following marketing; (d) obtaining all necessary governmental approvals for the activities in (a); and (e) spending at least $650,000 on the development of Licensed Products during the first four years of the License Agreement. As consideration for the license and other rights under the License Agreement, My Health Logic will pay Licensor annual royalties on net sales of Licensed Products, cover past patent costs, pay annual license maintenance fees and make certain payments upon the occurrence of milestone events in the regulatory approval process with respect to Licensed Products.

About the Company

Health Logic Interactive, through its wholly owned operating subsidiary My Health Logic, is developing and commercializing consumer focused handheld point-of-care diagnostic devices that connect to patient’s smartphones and digital continued care platforms. The Company plans to use their patent pending lab-on-chip technology to provide rapid results and facilitate the transfer of that data from the diagnostic device to the patient’s smartphone. The Company expects this data collection will allow it to better assess patient risk profiles and provide better patient outcomes. Our mission is to empower people with the ability to get early detection anytime, anywhere with actionable digital management for chronic kidney disease. For more information visit us at: www.healthlogicinteractive.com

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements, referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management’s expectations and intentions with respect to, among other things: development, manufacture and sale of Licensed Products; performance of obligations under the License Agreement; plans to engage the inventors and other experts to assist with regulatory approval and commercialization of Licensed Products; plans for and expected benefits of the licensed technology; and the Offering.

These forward-looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: My Health Logic’s ability to develop, manufacture and sell the Licensed Products, perform its obligations under the License Agreement and otherwise implement its business strategies; My Health Logic’s ability to obtain regulatory approval of Licensed Products; and the Company’s ability to obtain regulatory approval of the Offering and complete the Offering on the proposed terms.

In making the forward looking statements in this news release, the Company has applied several material assumptions, including without limitation, that: My Health Logic will be able to develop, manufacture and sell the Licensed Products, perform its obligations under the License Agreement and otherwise implement its business strategies; My Health Logic will be able to obtain all necessary regulatory approvals with respect to Licensed Products; and the Company will be able to obtain all necessary regulatory approvals with respect to the Offering, and the Company will be able to complete the Offering on the proposed terms.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

SOURCE Health Logic Interactive Inc.

For further information: contact George Kovalyov, Director, info@healthlogicinteractive.com, 1-877-456-4424.

Related Links

https://www.healthlogicinteractive.com/

Health Logic Interactive Inc., Announces Research Agreement to Develop Lab-On-Chip Medical Technologies

NEX: CHIP

CALGARYMarch 19, 2021 /CNW/ – Health Logic Interactive Inc. (“Health Logic” or the “Company“) (NEX: CHIP), through its wholly owned operating subsidiary, My Health Logic Inc. (“My Health Logic“), is pleased to announce a medical technology Research Agreement between My Health Logic and a leading Canadian University.

Dr. Francis Lin will be leading the research and development of multiple patent-pending and innovative microfluidic (lab-on-chip) technologies that connect to smartphones for the diagnosis and management of various chronic disease conditions.

Dr. Lin has been working on several next generation lab-on-chip (“LOC”) technologies for rapid disease diagnosis and assessment. To date, Dr. Lin has developed a LOC for the assessment of chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and many others. In close collaboration with renowned medical research teams Dr. Lin’s platform technologies have been validated clinically and the team has been publishing in leading multidisciplinary and biomedical journals, such as ACS Sensorsnpj Digital Medicine (Nature)  and PLOS ONE.

“I’m ecstatic to be working with My Health Logic and believe the Company is truly visionary for sponsoring LOC technologies and its future potential. We continue to strive toward bringing accurate and cost-effective lab equivalent results to the convenience of your home.” – Dr. Francis Lin

Dr. Francis Lin

  • 20 years’ experience in lab-on-chip technology development and lead inventor of multiple LOC patents.
  • Past chair of biophysics and medical physics division for the Canadian Association of Physicists.
  • Recently appointed to the Editorial Board of the peer reviewed journal ‘Microsystems and Nanoengineering’ published by Springer Nature.
  • Ph.D and postdoc training in biophysics, biomedical engineering, and immunology at University of California Irvine and Stanford University.
  • Over 80 peer-reviewed publications.

About the Company

Health Logic Interactive Inc. plans to develop and commercialize novel technologies through its wholly owned operating subsidiary, My Health Logic Inc. At the present time, the company is not engaged in active business operations. The company intends to acquire and commercialize consumer focused healthcare technologies that address areas of unmet needs. However, to date it has not entered into any binding agreements for such acquisitions and there can be no guarantee that the company will be able to successfully identify, negotiate and complete such acquisitions or raise the necessary financings for such acquisitions or for the development of its business should it be able to complete such acquisitions.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Health Logic Interactive Inc.

For further information: George Kovalyov, Director, info@healthlogicinteractive.com, 1-877-456-4424.

Health Logic Interactive Inc. Announces the Appointment of Dr. Marta New, MBA to the Advisory Board

NEX: CHIP

CALGARY, AB, March 17, 2021 /CNW/ – Health Logic Interactive Inc. (“Health Logic” or the “Company”) (NEX: CHIP), is pleased to announce through its wholly owned operating subsidiary, My Health Logic Inc. (“My Health Logic”), the hiring of Dr. Marta New as a strategic advisor to the Company. Dr. New will be instrumental in the Company’s development as it continues its search for online digital health platforms and digitally connected medical devices.

Dr. New is founder and CEO of Radyus Research, a highly regarded contract research organization focused on preclinical drug development services combined with comprehensive scientific and strategic consulting. Dr. New was co-founding Partner at Agent Capital, participating in multiple venture capital investments including Orchard Therapeutics (NASDAQ:ORTX) and Precision Biosciences (NASDAQ:DITL), among others. Dr. New began her investment career at Baxter Ventures, focusing on medical devices, diagnostics, and therapeutic investments strategic to Baxter, including Chronic Kidney Disease. She also spent several years at Baxter’s Global Renal Marketing franchise, where she was the commercial lead for multiple new CKD products being launched in the U.S. and international markets.

“We are very excited to have Dr. New as a part of our team, her strong experience in successfully financing and commercializing medical devices and diagnostics will be of significant value as our Company continues to grow.”

– David Barthel, CEO

About the Company

Health Logic Interactive Inc. plans to develop and commercialize novel technologies through its wholly owned operating subsidiary, My Health Logic Inc. At the present time, the company is not engaged in active business operations. The company intends to acquire and commercialize consumer focused healthcare technologies that address areas of unmet needs. However, to date it has not entered into any binding agreements for such acquisitions and there can be no guarantee that the company will be able to successfully identify, negotiate and complete such acquisitions or raise the necessary financings for such acquisitions or for the development of its business should it be able to complete such acquisitions.

Further information regarding Health Logic Interactive Inc. and its disclosure documents are available on SEDAR at www.sedar.com.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Health Logic Interactive Inc.

For further information: George Kovalyov, CEO, info@healthlogicinteractive.com, 1-877-456-4424.

Related Links

Home

Health Logic Interactive Inc. Announces Revival of Wholly Owned Subsidiary FanLogic Holdings Ltd. Including Name Change to My Health Logic Inc.

CALGARY, ABMarch 15, 2021 /CNW/ – Health Logic Interactive Inc. (“Health Logic” or the “Company“) (NEX: CHIP), is pleased to announce the reinstatement and name change of FanLogic Holdings LTD., the Company’s wholly owned subsidiary, to My Health Logic Inc. (“My Health Logic” or the “Subsidiary”) in the province of Alberta, Canada. The Company, through its wholly owned operating subsidiary My Health Logic Inc. will engage in the search of online digital health platforms and digitally connected medical devices.

Companies interested in applying to partner with, seek investment from, or be acquired by Health Logic Interactive Inc. may contact us here at info@healthlogicinteractive.com.

About the Company

Health Logic Interactive Inc. plans to develop and commercialize novel technologies. At the present time, the Company is not engaged in active business operations. The Company intends to acquire and commercialize consumer focused healthcare technologies that address areas of unmet needs. However, to date it has not entered into any binding agreements for such acquisitions and there can be no guarantee that the Company will be able to successfully identify, negotiate and complete such acquisitions or raise the necessary financings for such acquisitions or for the development of its business should it be able to complete such acquisitions.

Further information regarding Health Logic Interactive Inc. and its disclosure documents are available on SEDAR at www.sedar.com.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Health Logic Interactive Inc.

For further information: Contact George Kovalyov, Director, info@healthlogicinteractive.com, 1-877-456-4424.

Health Logic Interactive Inc. Announces NEX Trading Date, Debt Conversion Transactions and Proposed Private Placement

VANCOUVER, British Columbia, March 12, 2021 (GLOBE NEWSWIRE) — Health Logic Interactive Inc. (formerly FanLogic Interactive Inc.) (the “Corporation“) announces that, given the recent announcement that the Alberta Securities Commission has revoked its previously issued cease trade order in respect of the Corporation’s securities, and the completion the TSX Venture Exchange review, the TSX Venture Exchange subsequently lifted its trading suspension on the Corporation’s common shares which will be reinstated for trading effective March 15, 2021.   The Corporation also announces that it intends to convert certain debt of the Corporation and its subsidiary into equity of the Corporation at a deemed price of $0.05 per share, subject to the satisfaction of certain conditions set out herein.

Trading on NEX

As previously announced, the Corporation officially changed its name to “Health Logic Interactive Inc.”, changed its trading symbol to CHIP, and consolidated all of its issued and outstanding common shares on the basis of one post-consolidation share for every 10 pre-consolidation shares outstanding prior to the consolidation (resulting in 7,397,440 post-consolidations common shares being outstanding). The existing share certificates representing the pre-consolidation common shares issued under the former name of FanLogic Interactive Inc. will need to be exchanged for new post-consolidation common shares under the name Health Logic Interactive Inc. Each registered shareholder has previously been provided with a Transmittal Letter to complete and return to the Corporation’s transfer agent Computershare Trust Company of Canada.

The common shares of the Corporation will be reinstated for trading on the NEX board of the TSX Venture Exchange, and the name change and consolidation will be effective for trading purposes on the NEX, commencing at the opening of trading on March 15, 2021 with the common shares of the Corporation trading under the new trading symbol “CHIP“.

Conversion of First Promissory Notes

The Corporation also announces that, subject to the approval of the TSX Venture Exchange, the holders of an aggregate of $200,000 principal amount of secured, convertible promissory notes (the “First Notes“) previously issued by the Corporation have agreed to convert the principal and interest owing under such notes into 4,612,822 units (“First Note Units“) of the Corporation, a deemed price of $0.05 per First Note Unit (for aggregate consideration of $230,641), in full and final settlement of all principal ($200,000) and interest ($30,641) outstanding under such notes. Each First Note Unit consists of one common share in the capital of the Corporation (“Common Share“) and one common share purchase warrant (“First Note Warrant“), with each such First Note Warrant exercisable for a period of two years from the date of issuance for one additional Common Share of the Corporation at a price equal to $0.10 per share.

Subject to the approval of the TSX Venture Exchange to the conversion of the First Notes as discussed above, the holders of the First Notes have also agreed to exercise all of the First Note Warrants issued to them upon conversion of the First Notes resulting in the issuance of a further 4,612,822 common shares.

Each of the former First Note Holders has further agreed with the Corporation to not sell the Common Shares received upon conversion of the First Notes and exercise of the First Note Warrants, except in limited circumstances. Notwithstanding the foregoing,12.5% of the shares held by each such person will be released from these resale restrictions every 3 months for the next 24 months (with the first release being in June 2021).

The First Notes were issued by the Corporation on July 10, 2020 to fund the activities necessary to have the cease trade order previously issued by the Alberta Securities Commission revoked, to pay certain receivables and for general working capital purposes. The term of the First Notes was two years. The First Notes bore interest at a rate of 24% per annum and were convertible at the option of the holder into First Note Units at a post-consolidation price of $0.05 per First Note Unit in the first year and $0.10 per First Note Unit thereafter.

Conversion of Subsidiary Promissory Notes

The Corporation also announces that, subject to the approval of the TSX Venture Exchange, it will seek to obtain agreement with the arm’s length holders of an aggregate of $140,000 principal amount of unsecured promissory notes (the “Subsidiary Notes“) issued by a wholly-owned subsidiary of the Corporation to the assumption of the obligations under those notes by the Corporation and the issuance of 2,800,000 units (“Subsidiary Note Units“) of the Corporation, at a deemed price of $0.05 per Subsidiary Note Unit, in full and final settlement of all principal and interest outstanding under such notes. Each Subsidiary Note Unit will consist of one Common Share and one and one common share purchase warrant (“Subsidiary Note Warrant“). Each Subsidiary Note Warrant will be exercisable for a period of six months from the date of issuance for one additional Common Share of the Corporation at a price equal to $0.10 per share. Notwithstanding the foregoing, if at any time the volume weighted average trading price of the Common Shares on any Canadian securities exchange on which Common Shares become listed for trading (including the NEX board of the TSX Venture Exchange), for a period of 10 consecutive trading days equals or exceeds $0.20 (the “Acceleration Trigger Date“), the expiry date of the Subsidiary Note Warrants will be automatically accelerated to that date that is 30 Business Days after the Acceleration Trigger Date.

The Subsidiary Notes are due June 30, 2021 and bear no interest. The proceeds of the Subsidiary Notes were used, and are being used, to fund the working capital of the subsidiary, as it seeks business opportunities. All holders of Subsidiary Notes are arm’s length parties to the Corporation.

Conversion of the Subsidiary Notes is subject to certain conditions including execution of definitive binding agreements, the receipt of closing documentation and the approval of the TSX Venture Exchange. There is no guarantee that such conditions precedent will be satisfied or that any of the transactions will be completed as described herein or at all.

Conversion of Payables

The Corporation also announces that, subject to the approval of the TSX Venture Exchange, certain of its directors and officers have agreed to convert $217,933.31 payables owing to those persons (the “Insider Payables“) into common shares at a deemed price of $0.05 per share for an aggregate issuance of 4,359,866 Common Shares. Such amounts are owing to them for services rendered up to February 28, 2021 ($174,400 in aggregate) and for reimbursement of expenses incurred for the benefit of the Corporation ($43,593.31).

Each of the directors and officers has further agreed with the Corporation to not sell the Common Shares received upon conversion of the Insider Payable owed to them, except in limited circumstances. Notwithstanding the foregoing,12.5% of the shares held by each such person will be released from these resale restrictions every 3 months for the next 24 months (with the first release anticipated to be in June 2021.

It is anticipated that the aforementioned transactions with the directors and officers will be exempt from the valuation and minority shareholder approval requirements of Multilateral Instrument 61-101 (“MI 61-101”) by virtue of the exemptions contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in that the fair market value of the shares to be issued to such insiders will not exceed 25% of the Corporation’s market capitalization at the time the transactions are agreed to.

Conversion of the Insider Payables is subject to certain conditions including execution of definitive binding agreements, the receipt of closing documentation and the approval of the TSX Venture Exchange. There is no guarantee that such conditions precedent will be satisfied or that any of the transactions will be completed as described herein or at all.

Arm’s Length Private Placement

The Corporation also announces that, subject to the approval of the TSX Venture Exchange, it proposes to complete an arm’s length financing of up to 1,020,000 units of the Corporation (“Private Placement Units”) at a price of $0.05 per Unitfor gross proceeds of up to $51,000 (the “Offering“). Each proposed Private Placement Unit consists of one common share of the Corporation (a “Common Share”) and one Common Share purchase warrant of the Corporation (a “Private Placement Warrant”). Each Private Placement Warrant shall entitle the holder thereof to acquire one Common Share in the capital of the Corporation (a “Private Placement Warrant Share”) at an exercise price of $0.10 per Private Placement Warrant Share for a period of six months from closing, subject to adjustment in certain events. Notwithstanding the foregoing, if at any time the volume weighted average trading price of the Common Shares on any other Canadian securities exchange on which Common Shares become listed for trading (including the NEX board of the TSX Venture Exchange), for a period of 10 consecutive trading days equals or exceeds $0.10 (the “Acceleration Trigger Date“), the expiry date of the Private Placement Warrants will be automatically accelerated to that date that is 10 Business Days after the Acceleration Trigger Date.

Closing of the Offering is subject to standard closing conditions including receipt of executed subscription agreements and subscription funds, the availability of prospectus exemptions for each investor and receipt of TSX Venture Exchange approval. There is no guarantee that such closing conditions will be satisfied or that any proceeds will be raised under the Offering.

Bonus Shares

The Corporation further announces that, subject to the approval of the TSX Venture Exchange, it has agreed to pay a bonus to certain of its directors and officers for their services in the event that any securities of the Corporation, or any successor to the Corporation, become listed for trading on the Toronto Stock Exchange, Aequitas NEO Exchange Inc., the New York Stock Exchange, the American Stock Exchange, the NASDAQ Stock Market, or the London Stock Exchange, provided such person continues to be a director, officer, employee or bona fide consultant off the Corporation on the date of such listing. The bonus to be paid via the issuance an aggregate of 1,000,000 common shares to 5 directors and officers (200,000 each),

About the Corporation

At the present time, the Corporation is not engaged in active business operations.  The Corporation intends to acquire and commercialize consumer focused healthcare technologies that address areas of unmet needs, such as chronic disease management through point-of-care diagnostic medical devices that are connected to patient’s smartphones and virtual continued care platforms. However, to date it has not entered into any binding agreements for such acquisitions and there can be no guarantee that the Corporation will be able to successfully identify, negotiate and complete such acquisitions or raise the necessary financings for such acquisitions or for the development of its business should it be able to complete such acquisitions.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Health Logic Interactive is Pleased to Announce the Appointment of Experienced MedTech Executive as CEO

CALGARY, AB, March 12, 2021 /CNW/ – Health Logic Interactive Inc. (“Health Logic” or the “Company“) (NEX: CHIP), is pleased to announce the hiring of Mr. David Barthel, as the Chief Executive Officer for Health Logic.

Mr. Barthel is an experienced executive leader in the medical device space with a successful track record.

Mr. Barthel founded The SmartPill and led the company as CEO & President until its acquisition by medical device giant, Medtronic (Nasdaq:MDT). Mr. Barthel successfully took The SmartPill company from its initial patent through the entire product development process, including raising over $70 million USD in multiple funding rounds. Mr. Barthel led his team through multiple clinical trials, manufacturing, FDA approval, and successful insurance reimbursement. After the acquisition by Medtronic, Mr. Barthel joined the company as Area Vice President, GIH Southeast Division. Mr. Barthel has also been active advising other leading MedTech companies, including Henry Schein’s Orthopedic Surgical Instrumentation business.

Mr. Barthel earned a Bachelor of Arts Degree from St. Norbert College in DePere, Wi and an MBA from Lake Forest Graduate School of Management in Lake Forest, II.

George Kovalyov, Director, stated the following: “We’re grateful to welcome an executive of David’s caliber and applicable experience to our young and growing company. David will be an invaluable asset and esteemed leader as we progress through 2021 raising capital and achieving milestones. David’s success of leading a medical device company through the product development process and to its ultimate sale to Medtronic, along with his continued upward trajectory of working at both Medtronic and Henry Schein, brings a desirable balance of both start-up hunger and big-pharma experience to build the best company from the start.”

About the Company

Health Logic Interactive Inc. plans to develop and commercialize novel technologies. At the present time, the company is not engaged in active business operations. The company intends to acquire and commercialize consumer focused healthcare technologies that address areas of unmet needs. However, to date it has not entered into any binding agreements for such acquisitions and there can be no guarantee that the company will be able to successfully identify, negotiate and complete such acquisitions or raise the necessary financings for such acquisitions or for the development of its business should it be able to complete such acquisitions.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Health Logic Interactive Inc.

For further information: George Kovalyov, Director, info@healthlogicinteractive.com, 1-877-456-4424

Health Logic Interactive Inc. (formerly FanLogic Interactive Inc.) has Cease Trade Order Revoked

VANCOUVER, British Columbia, March 08, 2021 (GLOBE NEWSWIRE) — Health Logic Interactive Inc. (formerly FanLogic Interactive Inc.) (the “Company”) announces that the Alberta Securities Commission has revoked its previously issued cease trade order in respect of the Company’s securities. On May 6, 2019, the Alberta Securities Commission issued a cease trade order with respect to trading in the Company’s securities due to the Company’s failure to file its annual audited financial statements, annual management’s discussion and analysis and certification of the annual filings for the year ended December 31, 2018. The Company has since filed those and other required continuous documents and filed an application with the Alberta Securities for the revocation of the cease trade order. On March 8, 2021, the Alberta Securities Commission revoked the cease trade order.

As previously announced, the Company officially changed its name to “Health Logic Interactive Inc.”, changed its trading symbol to CHIP, and consolidated all of its issued and outstanding common shares on the basis of one post-consolidation share for every 10 pre-consolidation shares outstanding prior to the consolidation. The existing share certificates representing the pre-consolidation common shares issued under the former name of Fanlogic Interactive Inc. will need to be exchanged for new post-consolidation common shares under the name Health Logic Interactive Inc. Each shareholder has been provided with a Transmittal Letter to complete and return to the Company’s transfer agent Computershare Trust Company of Canada.

About the Company

At the present time, the Company is not engaged in active business operations. The Company intends to acquire and commercialize consumer focused healthcare technologies that address areas of unmet needs, such as chronic disease management through point-of-care diagnostic medical devices that are connected to patient’s smartphones and virtual continued care platforms. However, to date it has not entered into any binding agreements for such acquisitions and there can be no guarantee that the Company will be able to successfully identify, negotiate and complete such acquisitions or raise the necessary financings for such acquisitions or for the development of its business should it be able to complete such acquisitions.

For more information, contact George Kovalyov, Director, info@myhealthlogic.com,, 1-877-456-4424.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.